# Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

> **NCT03940976** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 40 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT03940976
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-28
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-05-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03940976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03940976, "Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03940976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*